BioSpace News Archive

Genetown

Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference

Biogen announced today that it will present detailed data from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumab at the 10th Clinical Trials on Alzheimer’s Disease Conference meeting in Boston.

October 30, 2017

·

1 min read

Business

PerkinElmer Elects Pascale Witz to Its Board of Directors

Witz has more than 30 years of global experience, most recently serving as executive vice president, Global Diabetes and Cardiovascular for Sanofi, S.A.

October 30, 2017

·

2 min read

Genetown

Alnylam to Webcast Conference Call Discussing Third Quarter 2017 Financial Results

Management will provide an update on the Company and discuss third quarter 2017 results as well as expectations for the future via conference call on Tuesday, November 7, 2017 at 4:30 p.m. ET.

October 30, 2017

·

2 min read

Lombard Medical Announces Shares to Trade on OTCQX

Lombard anticipates that its common shares will trade under its existing ticker symbol EVAR on the OTCQX Market effective as of the market open on November 9, 2017.

October 30, 2017

·

3 min read

Business

Kare Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017

Kare has extensive global pharmaceutical experience and a strong track record in corporate turnarounds, as well as in driving growth and leading international expansion.

October 30, 2017

·

8 min read

Relevium Files and Provides Comments on the Audited Consolidated Financial Statements for the Fiscal Year Ended June 30, 2017 and 2016

The Company reported significant changes to the Consolidated Statements of Financial Position, including an increase in total assets of $6,111,470 from $1,003,682 in 2016 to $7,115,152 in 2017.

October 30, 2017

·

4 min read

Business

Orthofix International Reports Third Quarter 2017 Financial Results

Net sales were $105.2 million, diluted earnings per share from continuing operations was $0.18 and adjusted earnings per share from continuing operations was $0.42.

October 30, 2017

·

18 min read

Drug Development

Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma

The Rare Pediatric Disease Designation of 9-ING for the treatment of pediatric neuroblastoma comes in addition to Orphan Drug Designations previously granted by the FDA for neuroblastoma, and separately,

October 30, 2017

·

3 min read

Business

Theradiag Release: Revenues at the End of September 30, 2017

During the period to September 30, 2017, Theradiag generated consolidated revenues of €6.8 million, up +7% compared with 2016.

October 30, 2017

·

2 min read

Business

Impax Announces Consent Solicitation

Impax announced today the commencement of a consent solicitation with respect to its 2.00% Convertible Senior Notes due 2022.

October 30, 2017

·

8 min read